Navigation Links
Cohera Medical Secures $16.1 Million in Series B Financing
Date:10/17/2008

PITTSBURGH, Oct. 17 /PRNewswire/ -- Cohera Medical Inc. today announced it has secured $16.1 million in a Series B financing for the ongoing development of TissuGlu(R), a novel surgical adhesive for application in plastic surgery.

The financing, which was led by Bradford Capital Partners, included participation from existing investors led by Kern Whelan Capital, LLC. The angel financing provides the company with sufficient capital to advance TissuGlu into clinical trials, which are expected to begin early next year.

"Kern Whelan Capital is delighted to support this second round of financing by doubling our initial investment," said Jay Kern, operating partner. "We believe there is a huge market potential in many applications for Cohera's products."

"TissuGlu has great promise in tummy tuck and other plastic surgery indications," said Marty Calihan, partner, Bradford Capital Partners. "Moreover, the company's core technology has significant potential for other uses, including mesh fixation and orthopedic applications. We view Cohera Medical's unique lead product and technology chassis as having tremendous potential to meet multiple needs of surgeons and their patients for which there are few options today."

Patrick Daly, chief executive officer of Cohera Medical, said "Our closing of this significant angel financing round in the current economic environment is a testament to the potential of our surgical adhesive technology. The financing gives us the capital to move forward with our clinical program for TissuGlu and affords us the opportunity to continue development of our other products."

About Cohera Medical

Cohera Medical Inc. is a Pittsburgh-based company that is developing a revolutionary line of wound management products and surgical adhesives. Cohera Medical's products are based on a unique chemical design that is purely synthetic, easy to use, biocompatible and fully resorbable. The company's lead product in development, TissuGlu, is a sprayable bonding agent for plastic surgery procedures. TissuGlu adheres flaps of tissue after surgical procedures, eliminating the spaces where fluid accumulates and reducing wound drainage. Cohera Medical is also developing surgical adhesives targeting mesh fixation and small bone fixation, which will fill similar market needs in both orthopedics and general surgery. For more information, visit http://www.coheramed.com. TissuGlu and the other Cohera products have not yet been approved for medical use by the Food and Drug Administration (FDA) in the U.S. or by any other country's regulatory authority.

Certain statements made throughout this press release that are not historical facts contain forward-looking statements regarding the company's future plans, objectives and expected performance. Any such forward-looking statements are based on assumptions that the company believes are reasonable, but are subject to a wide range of risks and uncertainties and, therefore, there can be no assurance that actual results may not differ materially from those expressed or implied by such forward-looking statements.


'/>"/>
SOURCE Cohera Medical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Cohera Medical Names Richard L. Wonsettler as Companys First CFO
2. Data Published in Plastic and Reconstructive Surgery Show Cohera Medicals Surgical Adhesive, TissuGlu(R), Prevents Seroma Formation in Animal Abdominoplasty Model
3. KePROs Chief Medical Officer to Present and Participate in Physician Roundtable at McKesson Health Solutions Conference
4. InHealth awards grants to study impact of medical diagnostics and devices on patients, health care
5. Clinicians in Netherlands Treat Lung Cancer Patients Using New RapidArc Radiotherapy Technology from Varian Medical Systems
6. Houston Northwest Medical Center Receives Clinical Excellence Awards for Several Service Lines
7. LegalView Reintroduces its Medical Malpractice Information Portal with Updated Links to Finding Immediate Legal Assistance
8. Sutter Medical Center Breaks Ground on Historic Womens and Childrens Center
9. Integrated Medical Systems Receives FDA Clearance for Worlds First Suitcase Intensive Care Unit
10. Frost & Sullivan Awards Infor-Med for its Electronic Medical Record Technology
11. Geisinger Medical Center earns prestigious Magnet designation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... ... January 18, 2017 , ... The VA Maryland ... collaborating on a research project focused on multiple sclerosis (MS). Led by Christopher ... nanotechnology to control the disease without compromising normal immune function that often occurs ...
(Date:1/18/2017)... CA (PRWEB) , ... January 18, 2017 , ... ... pleased to announce that their Vice President of Franchise Development, Paula Turner Pizarro, ... This award-winning business program, which features the insights of top business leaders from ...
(Date:1/18/2017)... ... 2017 , ... Catalent Pharma Solutions, the leading global provider ... products, today announced that Mr. Michael Merges, Director of Strategic Growth, Catalent Biologics ... at the Mayflower Hotel, Washington DC, on Jan. 24 – 26, 2017. , ...
(Date:1/18/2017)... ... , ... Floundering on New Year’s resolutions? Need an excuse to get back ... The U.S. Apple Association agrees and recommends starting each day with apples, a ... heart disease. , The U.S. Apple Association – which represents apple growers and producers ...
(Date:1/17/2017)... ... 2017 , ... For breast cancer clinicians and researchers who were unable to ... more intimate review and analysis of its highlights, a novel half-day, complimentary meeting—the 14th ... Imedex on February 4, 2017 in Chicago. Chaired by Kathy S. Albain, MD, FACP, ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... HARRISBURG, Pa. , Jan. 17, 2017 ... Drug and Alcohol Programs Secretary Gary Tennis ... with carfentanil, following two recent overdose deaths from the ... "Carfentanil is intended to sedate large animals ... potentially kill anyone who comes into contact with it," ...
(Date:1/17/2017)... 2017 EU5 Glucose Monitoring Market Outlook to ... Glucose Monitoring Market Outlook to 2022", provides key market ... provides value, in millions of US dollars, volume (in ... Blood Glucose Meters, Blood Glucose Test Strips and Lancets. ... shares data for each of these market segements, and ...
(Date:1/17/2017)... NEW YORK , Jan. 17, 2017 ... USD 8.02 billion by 2021 from USD 6.35 billion ... major factors driving the growth of this market are ... increasing demand for minimally invasive surgeries. The ... type, procedure, application, and region. On the basis of ...
Breaking Medicine Technology: